Satellos Bioscience Inc. SEC filings document the regulatory record of a Canadian clinical-stage biotechnology issuer focused on degenerative muscle diseases. Recent filings identify Satellos as a foreign issuer that submits current reports on Form 6-K and indicates Form 40-F reporting status.
For MSLE, the most relevant filings often involve clinical program updates, press releases furnished as exhibits, interim financial statements, management discussion and analysis, shareholder meeting results, and financing agreements. The company’s filings have included materials related to forazapadin, formerly SAT-3247, an orally administered small molecule therapeutic candidate designed to restore muscle regeneration in Duchenne muscular dystrophy and other degenerative muscle disease or injury conditions.
Satellos filings can help investors review the official language behind clinical news, including descriptions of BASECAMP and TRAILHEAD, regulatory designations for the DMD program, and statements that the candidate is not yet approved by any health authority. They also provide context on corporate governance through shareholder meeting disclosures and on capital markets activity through registration statements, sales agreements, and related exhibits.
Quarterly and annual foreign issuer materials are especially important for a development-stage biotech company because they connect trial activity with financial statements, risk discussion, and corporate plans. Form 6-K exhibits can also show how the company communicates clinical data, FDA interactions, investor presentations, and other events that may shape the public record for Satellos Bioscience stock.
Satellos Bioscience Inc. received U.S. Patent No. 12,747,245, a composition-of-matter patent covering forazapadin and a broader class of AAK1 inhibitors and related compounds. It provides intellectual property protection through September 6, 2044. Following potential U.S. marketing approval, Satellos may be eligible for a Patent Term Extension and intends to seek listing in the FDA’s Orange Book. For DMD, ongoing Phase 2 studies include BASECAMP, a global, randomized, placebo-controlled study in pediatric participants, and TRAILHEAD, an open-label study in adults. A Phase 2 study evaluating forazapadin in adults with FSHD is expected to begin in the fourth quarter of 2026.
Satellos Bioscience Inc. completed enrollment in BASECAMP, its Phase 2 trial of forazapadin for Duchenne muscular dystrophy in ambulatory boys ages 7 to 10. Satellos said it met and surpassed its enrollment target in less than nine months from screening its first participant.
Participants were randomized 1:1:1 to forazapadin 60 mg, forazapadin 120 mg or placebo. The study has a 12-week placebo-controlled period followed by a 36-week randomized active-treatment period. Primary endpoints include safety, tolerability and muscle force assessed by dynamometry. Satellos intends to share topline clinical data in Q1 2027.
Satellos Bioscience Inc. (MSLE) announced FDA clearance of its Investigational New Drug application for forazapadin in facioscapulohumeral muscular dystrophy (FSHD), its second clinical indication. The company expects to begin a Phase 2 FSHD study in Q4 2026. The planned study is for adults aged 18 and older and will evaluate orally administered 60 mg and 120 mg doses.
FSHD Canada Foundation agreed to provide up to US$5 million in milestone payments over the next five quarters, in exchange for a capped revenue-sharing interest in future FSHD-related proceeds. The financing is expected to support a randomized, double-blind, placebo-controlled proof-of-concept study assessing safety, tolerability, pharmacokinetics and potential efficacy.
Satellos also reported preliminary data from its ongoing Phase 2 DMD study in adults: after six months at 60 mg, results showed a favorable safety profile, reduced muscle fat fraction measured by MRI and increased total effort. The company said the findings may be consistent with muscle regeneration.
Satellos Bioscience Inc. (MSLE) reports that it will present four scientific posters on its lead drug candidate forazapadin (SAT-3247) at the 31st Annual Congress of the World Muscle Society in Hiroshima, Japan from September 29 to October 3, 2026. The presentations cover Phase 2 clinical studies in Duchenne muscular dystrophy (DMD), including the BASECAMP randomized, placebo-controlled trial in pediatric participants and the TRAILHEAD open-label study in adults, as well as translational biomarker work and the design of a study in facioscapulohumeral muscular dystrophy (FSHD). Satellos describes forazapadin as an oral AAK1 inhibitor intended to restore muscle repair and regeneration independently of dystrophin, and states that it plans to submit an Investigational New Drug application for FSHD and begin related clinical research in the second half of 2026, while expecting its current cash resources to provide a runway through 2027.
Satellos Bioscience Inc. (MSLE) reports that the World Health Organization has assigned the International Nonproprietary Name “forazapadin” to its lead orally administered small molecule drug candidate previously known as SAT-3247, which is designed to restore muscle regeneration in degenerative muscle diseases.
Forazapadin, an AAK1-targeting candidate, is being evaluated in two Phase 2 studies in Duchenne muscular dystrophy, including BASECAMP in pediatric participants and TRAILHEAD in adults, and Satellos plans a Phase 2 trial in facioscapulohumeral muscular dystrophy by the end of 2026. The company cites significant momentum in its Duchenne programs, with expected BASECAMP enrollment completion this quarter and clinical data in the fourth quarter, and states that its current cash, cash equivalents and short-term investments are expected to fund operations through 2027.
Satellos Bioscience Inc. (MSLE), a clinical-stage company focused on muscle regeneration therapies, reported that its management will present at two New York investor conferences in September 2026. The company is advancing SAT-3247, an oral AAK1 inhibitor, as a potential disease-modifying treatment for Duchenne muscular dystrophy (DMD), with two ongoing Phase 2 trials: BASECAMP in pediatric participants and TRAILHEAD in adults. Satellos also plans to submit an Investigational New Drug application and start clinical research in facioscapulohumeral muscular dystrophy (FSHD) in the second half of 2026. Management disclosed an expectation that current cash, cash equivalents and short-term investments will fund operations with a cash runway through 2027.
Satellos Bioscience Inc. has entered into a Sales Agreement with Leerink Partners LLC to establish an at-the-market equity offering program. Under this arrangement, Satellos may, from time to time, issue and sell up to $50,000,000 of its common shares through Leerink as sales agent, subject to board-authorized limits and available capacity under its shelf registration.
Sales will be made only in the United States as an “at the market offering” under Rule 415(a)(4), primarily through Nasdaq or other U.S. trading markets, at prevailing market prices. No offers or sales will occur in Canada or over Canadian exchanges. Leerink will use commercially reasonable efforts to place shares but is not obligated to buy them as principal without a separate agreement.
The ATM program is issued off Satellos’ previously filed short form base shelf prospectus and related Form F-10 registration statement, which provide for the potential offer and sale of up to $300,000,000 of securities overall. The company retains full discretion over when to deliver placement notices, the size and timing of sales, and may suspend or terminate offerings at any time.
Satellos Bioscience Inc. is a clinical-stage biotech focused on small‑molecule treatments for degenerative muscle diseases, led by SAT‑3247 for Duchenne muscular dystrophy (DMD). For the six months ended June 30, 2026, it reported a net loss of $21,486 (vs. $11,749 in 2025) as research and development and general and administrative expenses increased with the ramp-up of Phase 2 BASECAMP and TRAILHEAD trials and public-company costs.
R&D expenses rose to $16,945 for the six-month period, while G&A reached $5,263. The company has no revenue and an accumulated deficit of $103,456. Liquidity improved after a February 2026 equity offering raising $51,901 in net proceeds, bringing cash and short-term investments to $61,839 as of June 30, 2026; management believes this funds planned operations for the next 12 months.
Clinical and regulatory momentum continued: SAT‑3247 has Orphan Drug, Rare Pediatric Disease, and, as of June 29, 2026, Fast Track designation from the FDA for DMD. BASECAMP is enrolling 51 ambulatory boys with DMD globally, and TRAILHEAD is following adult DMD participants over 12 months, with interim data showing biomarker and imaging signals consistent with prior Phase 1 findings.
Satellos Bioscience Inc. filed an amended and restated short form base shelf prospectus and Form F-10 to register up to US$300,000,000 of common shares, preferred shares, warrants, units, subscription receipts and debt securities that may be offered over a 25‑month period. Specific terms, pricing, and structures will be set in future prospectus supplements and may include both fixed and non-fixed price distributions via underwriters, dealers, agents or direct sales. As of March 31, 2026, Satellos reported cash, cash equivalents and short-term investments of US$69.9 million and working capital of US$70.66 million, and intends to use any net proceeds primarily for R&D, advancing lead drug candidate SAT‑3247 through clinical trials, and general corporate purposes. Satellos is a clinical-stage company focused on degenerative muscle diseases; SAT‑3247 has FDA Fast Track designation for Duchenne and is being evaluated in ongoing clinical trials, with six‑month interim TRAILHEAD data in adults showing signals such as reduced muscle fat fraction and stable strength.
Satellos Bioscience reported six-month interim data from TRAILHEAD, an open-label Phase 2 study of SAT-3247 in four adults with Duchenne muscular dystrophy. MRI muscle fat fraction improved on average from 49.7% at baseline to 46.0% at month 6, a 3.7% absolute reduction. Mean total effort (TE99C) rose about 34%, from 16.1 joules/kg in the prior CL-101 study to 21.6 at month 6, while upper extremity strength measures, including handgrip, remained stable after a near-doubling seen in CL-101. Mean creatine kinase declined 38% from 2130 u/l to 1315 u/l. SAT-3247 was well tolerated with no serious treatment-emergent adverse events, no discontinuations, 100% compliance and about 186 days of mean exposure. Patient-reported fatigue (PedsQL-MFS) improved by 6.94 points, and Performance of the Upper Limb 2.0 scores were stable or slightly better. Satellos reiterates plans to complete BASECAMP pediatric enrollment and initiate U.S. TRAILHEAD sites in Q3 2026, with BASECAMP topline and TRAILHEAD 12‑month readouts expected in Q4 2026.